 Merck IBD Investors.com Investors.com Powered by Investors Business Daily
Investor's Business Daily Digital Edition
 |  To save time in the future, you may select one of the preferences below.You may update your IBD preferences at any time by going into My IBD and selecting Update Your IBD Preferences.Set Web Based Version as Default Set PDF Version as Default Set Recent Issues as Default  Add to your lists:
Posted 04/05/2010 06:28 PM ET
 Featured Stocks
 * Top Rated Company  , the drugmaker, is suing to stop rival Novartis'  Sandoz unit from selling a generic version of its antifungal drug Cancidas.The suit could prevent the FDA from approving Sandoz's generic for 30 months, or until the litigation is resolved.Merck<b><font color='red'> fell 0.9 %</font></b> to 37.39.Comments  Leave a Comment
 To participate in Community areas, please Registration Benefits
Not a member?Register &raquo;
Unregistered subscriber?Register &raquo;
Can't access your account?&raquo;
04/23/2010 05:00:24 PM ET
04/23/2010 05:00:15 PM ET
A few signs can alert you to corporate fraud.
 